Ami Fadia

Q: What is Ami Fadia's success rate?

Ami Fadia currently has a success rate of 89.89053492464977.

Q: What is the average return of Ami Fadia's calls?

Their stock ratings have generated an average return of 21.110801041059684.

Needham | Healthcare

Ami Fadia is an analyst from Needham specializing in the Healthcare sector. Ranked #1294 out of 4565 analysts, they have issued 65 stock ratings with a success rate of 89.89% and an average return of 21.11%.

Ami Fadia has a well-established track record, with 65 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 89.89% and an average return of 21.11%, underscoring their expertise and ability to identify winning opportunities for investors.

#1294

Out of 4565

Total Ratings

+89.89%

Success Rate

+21.11%

Average Return

Recent Ratings Analysis

IMRX

Buy

Mar 09, 2026

Target

$11.00

Current

$5.33

Performance

Ami Fadia rated IMRX as Buy on Mar 09, 2026, setting a price target of 11. Shares have remained stable near 5.33, leaving the 11 target still in play.

ATAI

Buy

Mar 09, 2026

Target

$14.00

Current

$3.39

Performance

On Mar 09, 2026, ATAI was given a Buy rating by Ami Fadia, with a target price of 14. The stock traded sideways with a % move, keeping the bullish thesis unresolved.

DAWN

Hold

Mar 06, 2026

Target

$0.00

Current

$21.20

Performance

0.00%

DAWN received a Hold rating from Ami Fadia on Mar 06, 2026, aiming for null. Shares remained flat at 21.2, aligning with the neutral rating.

GHRS

Buy

Mar 06, 2026

Target

$32.00

Current

$15.93

Performance

0.00%

On Mar 06, 2026, Ami Fadia published a Buy outlook on GHRS, with a target of 32. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 15.93.

RVMD

Buy

Feb 26, 2026

Target

$150.00

Current

$98.40

Performance

-3.67%

Ami Fadia on Feb 26, 2026 assigned RVMD a Buy rating, with a price target of 150. The recommendation remains pending validation as shares consolidate around 98.4.

HRMY

Buy

Feb 25, 2026

Target

$46.00

Current

$28.33

Performance

0.50%

On Feb 25, 2026, Ami Fadia reaffirmed HRMY with a Buy rating, targeting 46. Market indecision has kept the 46 target in a holding pattern.

AXSM

Buy

Feb 23, 2026

Target

$225.00

Current

$162.33

Performance

-7.11%

AXSM was rated Buy by Ami Fadia on Feb 23, 2026, with a price objective of 225. This case shows how bullish projections can fail, with the stock now below 162.33.

NBIX

Buy

Feb 12, 2026

Target

$187.00

Current

$128.13

Performance

4.09%

On Feb 12, 2026, Ami Fadia initiated coverage on NBIX with a Buy rating and target of 187. Neutral price movement of 4.09% leaves room for interpretation.

PRAX

Buy

Feb 04, 2026

Target

$510.00

Current

$310.71

Performance

2.43%

Ami Fadia issued a Buy recommendation for PRAX on Feb 04, 2026, price target set at 510. The target of 510 remains in play, though confirmation will depend on future moves.

JAZZ

Buy

Jan 12, 2026

Target

$235.00

Current

$182.01

Performance

11.20%

On Jan 12, 2026, JAZZ was evaluated by Ami Fadia, who gave a Buy rating and target of 235. This case illustrates how a timely bullish rating can translate into tangible gains of 11.20%.

COGT

Hold

Dec 08, 2025

Target

$0.00

Current

$37.08

Performance

-7.99%

Ami Fadia rated COGT as Hold on Dec 08, 2025, setting a price target of null. The cautious Hold call aligned with subsequent weakness, as shares slipped 7.99%.

ACAD

Buy

Nov 06, 2025

Target

$29.00

Current

$22.16

Performance

2.36%

On Nov 06, 2025, ACAD was given a Buy rating by Ami Fadia, with a target price of 29. The stock traded sideways with a 2.36% move, keeping the bullish thesis unresolved.

ALKS

Buy

Oct 29, 2025

Target

$44.00

Current

$28.63

Performance

-8.97%

ALKS received a Buy rating from Ami Fadia on Oct 29, 2025, aiming for 44. The rating hasn’t played out as hoped, with the stock trading 8.97% below expectations.

NMRA

Buy

Oct 28, 2025

Target

$8.00

Current

$3.02

Performance

16.60%

On Oct 28, 2025, Ami Fadia published a Buy outlook on NMRA, with a target of 8. Shares gained 16.60%, underscoring the accuracy of the bullish outlook toward 8.

AVDL

Hold

Oct 22, 2025

Target

$0.00

Current

$21.64

Performance

16.85%

Ami Fadia on Oct 22, 2025 assigned AVDL a Hold rating, with a price target of null. Shares outperformed expectations, climbing 16.85% despite the neutral view.

MNMD

Buy

Oct 13, 2025

Target

$28.00

Current

$17.69

Performance

44.41%

On Oct 13, 2025, Ami Fadia reaffirmed MNMD with a Buy rating, targeting 28. The recommendation was supported by strong follow-through as the stock rose from 17.69 to 17.69.

MRUS

Hold

Sep 29, 2025

Target

$96.00

Current

$90.00

Performance

-3.92%

MRUS was rated Hold by Ami Fadia on Sep 29, 2025, with a price objective of 96. Flat performance suggests the Hold view was reasonable.

BIIB

Hold

Sep 24, 2025

Target

$0.00

Current

$184.87

Performance

34.28%

On Sep 24, 2025, Ami Fadia initiated coverage on BIIB with a Hold rating and target of null. The Hold stance underestimated the stock’s strength as it gained 34.28%.

SAGE

Hold

Jun 16, 2025

Target

$0.00

Current

$8.68

Performance

-4.30%

Ami Fadia issued a Hold recommendation for SAGE on Jun 16, 2025, price target set at null. The rating was appropriate for a consolidating market trading near 8.68.

BCYC

Buy

Apr 09, 2025

Target

$30.00

Current

$5.20

Performance

-24.42%

On Apr 09, 2025, BCYC was evaluated by Ami Fadia, who gave a Buy rating and target of 30. Investors saw limited payoff as shares fell short of the 30 target.

BPMC

Buy

Apr 08, 2025

Target

$133.00

Current

$129.46

Performance

63.42%

Ami Fadia rated BPMC as Buy on Apr 08, 2025, setting a price target of 133. The call has proven timely, with shares rising 63.42% toward the price target of 133.

ITCI

Hold

Feb 21, 2025

Target

$0.00

Current

$131.87

Performance

2.54%

On Feb 21, 2025, ITCI was given a Hold rating by Ami Fadia, with a target price of null. Market indecision, reflected in sideways trading near 131.87, supported the cautious call.

Frequency Asked Questions

Who is Ami Fadia?

Ami Fadia is an analyst from Needham specializing in the Healthcare sector.

What is Ami Fadia's success rate?

Ami Fadia currently has a success rate of +89.89%.

How many ratings has Ami Fadia issued?

Ami Fadia has issued 65 stock ratings so far.

What is the average return of Ami Fadia's calls?

Their stock ratings have generated an average return of +21.11%.

What is Ami Fadia's ranking?

Ami Fadia is ranked #1294 out of 4565 analysts.

What types of ratings does Ami Fadia give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Ami Fadia?

You can follow Ami Fadia by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Ami Fadia?

Their latest rating was a Buy on IMRX issued on 2026-03-09.